A mixture of antiviral nucleoside antibiotics produced by Streptomyces lysosuperificus. It contains at least 10 homologues comprising uracil, N-acetylglucosamine, an 11-carbon aminodialdose called tunicamine, and a fatty acid linked to the amino group of the tunicamine. The homologues vary in the composition of the fatty acid moiety.
Chemical ID:
MESH:D014415
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
1,2-dithiol-3-thione inhibits the reaction [Tunicamycin results in increased expression of EIF2AK3 mRNA]; [ATG5 protein mutant form results in increased susceptibility to Tunicamycin] which results in increased expression of EIF2AK3 mRNA; [Tunicamycin co-treated with HRAS protein] results in increased expression of EIF2AK3 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [1,2-dithiol-3-thione inhibits the reaction [Tunicamycin results in increased expression of EIF2AK3 mRNA]]; Bortezomib inhibits the reaction [1,2-dithiol-3-thione inhibits the reaction [Tunicamycin results in increased expression of EIF2AK3 mRNA]]; EIF2AK3 gene mutant form inhibits the reaction [Tunicamycin results in increased expression of ATF4 mRNA]; EIF2AK3 gene mutant form inhibits the reaction [Tunicamycin results in increased expression of ATF4 protein]; EIF2AK3 gene mutant form inhibits the reaction [Tunicamycin results in increased expression of ATF6 protein]; EIF2AK3 gene mutant form inhibits the reaction [Tunicamycin results in increased expression of DDIT3 protein]; EIF2AK3 gene mutant form inhibits the reaction [Tunicamycin results in increased expression of EIF2S1 protein]; EIF2AK3 gene mutant form inhibits the reaction [Tunicamycin results in increased expression of IBTK mRNA]; EIF2AK3 gene mutant form inhibits the reaction [Tunicamycin results in increased expression of IBTK protein]; EIF2AK3 gene mutant form inhibits the reaction [Tunicamycin results in increased phosphorylation of EIF2S1 protein]; Exenatide inhibits the reaction [Tunicamycin results in increased phosphorylation of EIF2AK3 protein]; Ketoconazole inhibits the reaction [Tunicamycin results in increased phosphorylation of EIF2AK3 protein]; PTPN1 gene mutant form promotes the reaction [Tunicamycin results in increased activity of and results in increased phosphorylation of EIF2AK3 protein]; Tunicamycin promotes the reaction [PTPN1 protein binds to EIF2AK3 protein]; Tunicamycin results in increased activity of and results in increased phosphorylation of EIF2AK3 protein
2-(4-chlorophenoxy)-N-(4-(2-(4-chlorophenoxy)acetamido)cyclohexyl)acetamide promotes the reaction [Tunicamycin results in increased phosphorylation of EIF2AK3 protein]; Tunicamycin results in increased expression of and results in increased phosphorylation of EIF2AK3 protein
7-methyl-5-(1-((3-(trifluoromethyl)phenyl)acetyl)-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine inhibits the reaction [Tunicamycin results in increased phosphorylation of EIF2AK3 protein]; ibutilide inhibits the reaction [Tunicamycin results in increased expression of EIF2AK3 protein]
